<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:"Palatino Linotype";
panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle20
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:90707959;
mso-list-template-ids:1165818688;}
@list l0:level1
{mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level2
{mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level3
{mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level4
{mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level5
{mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level6
{mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level7
{mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level8
{mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level9
{mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1
{mso-list-id:289940039;
mso-list-template-ids:-2048209000;}
@list l1:level1
{mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level2
{mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level3
{mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level4
{mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level5
{mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level6
{mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level7
{mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level8
{mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level9
{mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2
{mso-list-id:710810094;
mso-list-template-ids:-695831298;}
@list l2:level1
{mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level2
{mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level3
{mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level4
{mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level5
{mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level6
{mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level7
{mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level8
{mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level9
{mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3
{mso-list-id:818768822;
mso-list-template-ids:-813394906;}
@list l3:level1
{mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level2
{mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level3
{mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level4
{mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level5
{mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level6
{mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level7
{mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level8
{mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level9
{mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l4
{mso-list-id:936716043;
mso-list-template-ids:-78197860;}
@list l4:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l4:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5
{mso-list-id:1056703202;
mso-list-template-ids:-1771537688;}
@list l5:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l5:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l6
{mso-list-id:1211696821;
mso-list-template-ids:552507140;}
@list l6:level1
{mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l6:level2
{mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l6:level3
{mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l6:level4
{mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l6:level5
{mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l6:level6
{mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l6:level7
{mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l6:level8
{mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l6:level9
{mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l7
{mso-list-id:1405952592;
mso-list-template-ids:109876932;}
@list l7:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l7:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l7:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l7:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l7:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l7:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l7:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l7:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l7:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l8
{mso-list-id:1553495349;
mso-list-template-ids:2086189670;}
@list l8:level1
{mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l8:level2
{mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l8:level3
{mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l8:level4
{mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l8:level5
{mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l8:level6
{mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l8:level7
{mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l8:level8
{mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l8:level9
{mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Florida Department of Health Biomedical Research Grant Programs<span style="color:#1F497D"> (</span>pl</span></b><b><span style="font-size:12.0pt;font-family:"Palatino Linotype",serif">ease
notify Med-RA if you intend to submit a letter of intent for these programs)</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:#1F497D"><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__http://www.floridahealth.gov/provider-and-partner-resources/research/funding-opportunity-announcements/ApprovedFinalFY20-21BHCFOA1.pdf__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySud6sRQ8ZU$" target="_blank">William G. "Bill" Bankhead,
Jr., and David Coley Cancer Research Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Priority will be given to applications that address at least one of the following: lung cancer, breast cancer, prostate cancer, colon cancer, or melanoma. To balance the number of grants
awarded across Research Priorities, this year the Department will further prioritize applications that address the following:<o:p></o:p></span></p>
<ol style="margin-top:0in" start="1" type="1">
<li class="MsoNormal" style="mso-list:l3 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Reduction of mortality and morbidity as related to health disparities.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Improve screening accuracy and detection in high risk groups.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Resistance to front-line treatments in recurrent disease in the five cancers listed.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Research focused on sarcomas, or leukemia and other blood cancers.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">Examine the relationship between obesity and cancer, cancer treatment responsiveness, and cancer treatment-related morbidities.<o:p></o:p></span></li></ol>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Required letter of intent due July 29, 2020. Application due September 16, 2020.
<span style="color:red">Med-RA deadline to receive application draft documents: September 2.</span></span></b><span style="font-size:12.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__http://www.floridahealth.gov/provider-and-partner-resources/research/funding-opportunity-announcements/ApprovedFinalFY20-21JEKFOA1.pdf__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySudgispXfo$" target="_blank">James and Esther King Biomedical
Research Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of the program is to support research initiatives that address the health care problems of Floridians in the areas of tobacco-related cancer, cardiovascular disease, stroke,
and pulmonary disease. In order to balance the number of grants awarded across Research Priorities, this year the Department will prioritize applications that address the following:<o:p></o:p></span></p>
<ol style="margin-top:0in" start="1" type="1">
<li class="MsoNormal" style="mso-list:l1 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Reduction of mortality and morbidity as related to health disparities.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Improve screening accuracy and detection in high risk groups.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Prevention and treatment research evaluating programs for tobacco use reduction and prevention.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Prevention of the transition from electronic nicotine to combustible tobacco usage, or demonstrates the effectiveness of the use of electronic nicotine
in the reduction or elimination of the use of combustible tobacco.<o:p></o:p></span></li></ol>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Required letter of intent due July 29, 2020. Application due September 16, 2020.
<span style="color:red">Med-RA deadline to receive application draft documents: September 2.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__http://www.floridahealth.gov/provider-and-partner-resources/research/funding-opportunity-announcements/ApprovedFinalFY20-21LLBFOA2.pdf__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySudjFuTsqg$" target="_blank">Live Like Bella Pediatric
Cancer Research Initiative</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This FOA covers cancers that occur during the pediatric period, from birth to 21 years, and will provide grants for research to further the search for cures for pediatric cancer, by pursuing
the following goals: <o:p></o:p></span></p>
<ol style="margin-top:0in" start="1" type="1">
<li class="MsoNormal" style="mso-list:l8 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Significantly expand pediatric cancer research capacity in Florida.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l8 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Improve both research and treatment through greater pediatric enrollment in clinical trials networks.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l8 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Reduce the impact of pediatric cancer on disparate groups.<o:p></o:p></span></li></ol>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Required letter of intent due July 29, 2020. Application due September 16, 2020.
<span style="color:red">Med-RA deadline to receive application draft documents: September 2.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__http://www.floridahealth.gov/provider-and-partner-resources/research/funding-opportunity-announcements/CompletedFY2020-21FundingOpportunityAnnouncementfortheEdEthelMooreAlzheimersDiseaseResearchProgram_6_8_20.pdf__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySud8tYjGKw$" target="_blank">Ed
and Ethel Moore Alzheimer's Disease Research Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of the Program is to fund research leading to prevention of, or a cure for, Alzheimer’s disease by pursuing the following goals:<o:p></o:p></span></p>
<ol style="margin-top:0in" start="1" type="1">
<li class="MsoNormal" style="mso-list:l6 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">Improve the health of Floridians by researching better prevention and diagnoses of, and treatments and cures for, Alzheimer’s disease.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l6 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">Expand the foundation of knowledge relating to the prevention, diagnosis, treatment, and cure of Alzheimer’s disease.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l6 level1 lfo4"><span style="font-size:12.0pt;font-family:Palatino">Stimulate economic activity in Florida in areas related to Alzheimer’s disease research.<o:p></o:p></span></li></ol>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">High priority will be given to biomedical or behavioral clinical trial recruitment and participation in observational or experimental research studies that involve special populations
and underserved areas.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Required letter of intent due July 31, 2020. Application due September 9, 2020.
<span style="color:red">Med-RA deadline to receive application draft documents: August 26.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Congressionally Directed Medical Research Programs<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/pcarp__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySuduPMU9Z8$" target="_blank">Pancreatic Cancer Research Program</a><br>
<b>Idea Development Award</b><br>
Pre-application (preproposal): August 25, 2020. Application: November 2, 2020.<br>
<b>Translational Research Award</b><br>
Pre-application (preproposal): August 25, 2020. Application: November 2, 2020.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft application documents: October 20.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/rtrp__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySudaTANImg$" target="_blank">Reconstructive Transplant Research Program</a><br>
<b>Investigator Initiated Research Award</b><br>
Pre-application (preproposal): August 19, 2020. Application: November 12, 2020.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft application documents: October 29.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.charleskochfoundation.org/apply-for-grants/requests-for-proposals/communities/substance-abuse-research-grants/__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySudP3j75tw$" target="_blank">Charles Koch Foundation: Substance
Abuse Research Grants</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Charles Koch Foundation seeks to support research projects (e.g. papers, conferences, workshops, etc.) that explore innovative, community-based solutions that are targeted at destroying
the root causes of substance abuse. To that end, we are actively soliciting proposals for projects to consider innovative solutions that seek to alleviate substance use disorders. We are especially interested in research that:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l5 level1 lfo5"><span style="font-size:12.0pt;font-family:Palatino">Addresses innovative ways to help individuals overcome substance use disorders, prevent drug overdoses, and increase the willingness of individuals to
seek treatment for substance abuse.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l5 level1 lfo5"><span style="font-size:12.0pt;font-family:Palatino">Explores the root causes of addiction and substance use disorders as well as innovative means to prevent substance abuse by remedying these root causes.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l5 level1 lfo5"><span style="font-size:12.0pt;font-family:Palatino">Addresses the unintended consequences of current approaches to reduce drug overdoses and substance abuse.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l5 level1 lfo5"><span style="font-size:12.0pt;font-family:Palatino">Examines solutions that offer a proactive approach to fighting addiction rather than a reactive approach focusing on treatment and recovery.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l5 level1 lfo5"><span style="font-size:12.0pt;font-family:Palatino">Explores opportunities to reduce the stigma associated with substance use disorders and celebrate success in overcoming addiction and substance abuse.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Funding levels are commensurate with the requirements of the research and the potential for the research to advance an understanding of critical issues. Accepted proposals may also receive
support to disseminate the research findings.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Applications accepted on a rolling basis.
<span style="color:red">Med-RA deadline to receive draft documents: Ten business days before submission.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-EB-20-001.html__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySudK5mv0S8$" target="_blank">BRAIN Initiative: Proof of Concept Development of Early Stage Next Generation Human Brain Imaging
(R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support early stage development
of entirely new noninvasive imaging methods or unusually bold approaches for existing noninvasive imaging methods that will lead to transformative advances in our understanding of the function and connectivity of the human brain. The FOA solicits small-scale
projects to prove exceptionally innovative, original and/or unconventional concepts.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 3, 2020 and September 3, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for September 3, 2020 due date: August 24.</span></span></b><span style="font-size:12.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/rfa-eb-19-002.html__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySudMBM9Fys$" target="_blank">BRAIN Initiative: Development of Next Generation Human Brain Imaging Tools and Technologies (U01
Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support full development of
entirely new or next generation noninvasive human brain imaging tools and methods that will lead to transformative advances in our understanding of the human brain. The FOA seeks innovative applications that are ready for full-scale development of breakthrough
technologies with the intention of delivering working tools.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 3, 2020 and September 3, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for September 3, 2020 due date: August 24.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-EB-20-002.html__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySudrMMJDco$" target="_blank">BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01
Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This FOA solicits the development of theories, computational models, and analytical tools to derive understanding of brain function from complex neuroscience data. Proposed projects could
develop tools to integrate existing theories or formulate new theories; conceptual frameworks to organize or fuse data to infer general principles of brain function; multiscale/multiphysics models to generate new testable hypotheses to design/drive future
experiments; new analytical methods to either support or refute a stated hypothesis about brain function. It is expected that the tools developed under this FOA will be made widely available to the neuroscience research community for their use and modification.
Investigative studies should be limited to model parameter estimation and/or validity testing of the tools being developed.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 14, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: August 31.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-250.html__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySudxJObFZk$" target="_blank">NICHD Research Education Programs (R25 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This FOA invites applications to develop and conduct short-term research education programs to improve the knowledge and research skills of biomedical and behavioral scientists conducting
research in areas relevant to the mission of NICHD, including reproductive, developmental, behavioral, social, and rehabilitative processes that determine the health and well-being of newborns, infants, children, adults, families, and populations. Programs
must be unique and provide compelling value to students and/or investigators in the field. Depending on the goals of the proposed training programs, the duration of the short courses can vary from one week or less to a maximum of 12 weeks. Recurring courses
are allowed.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">R25 programs may be proposed in any research area relevant to the mission of NICHD. Areas of particular interest include:<o:p></o:p></span></p>
<ol style="margin-top:0in" start="1" type="1">
<li class="MsoNormal" style="mso-list:l0 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Training in specialized research techniques, research methodology, data sets, or statistical approaches.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Training in advanced approaches to clinical, translational, or basic research, for instance, training in design and implementation of clinical trials or
complex data collection projects.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Training in the use of model organisms or systems.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Short-term courses to expose upper undergraduates in the scientific areas that are within the scientific scope of the NICHD.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Specialized training on data sharing that addresses issues such as disclosure review, discoverability, multi-site access to restricted-access data, interoperability,
and other aspects of ensuring confidentiality and maximizing data accessibility.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Computational analysis of genomic data to identify genomic variants associated with structural birth defects.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Gene editing techniques for producing organisms modeling structural birth defects or studying genes involved with embryonic development.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Approaches toward analyzing and modeling developmental gene regulatory networks.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Collection of phenotypic and clinical data using controlled vocabularies and ontologies for standardized phenotyping of structural birth defects.<o:p></o:p></span></li></ol>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 26, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for September 25 standard date: September 11.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Cigna Healthier Kids for Our Future: Food Insecurity and Mental Health Grants<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.cybergrants.com/cigna/healthierkidsforourfuture/index.html__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySudhK47XQo$">Food Insecurity</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">We want to work with organizations that are on the ground, in the communities, working to address food security throughout the world. We have learned that schools—at least in the U.S.
and in many countries—are a focal point for addressing this issue and in most cases, already have programs supporting at-risk populations. With that in mind, we want to fill the gaps that exist in and outside the school environment.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">We are looking for programs that attempt to address these, and other gaps, in delivering food and nutritional education to children. The Cigna Foundation is looking for programs that bracket
or augment in-school efforts in the following areas:<o:p></o:p></span></p>
<ol style="margin-top:0in" start="1" type="1">
<li class="MsoNormal" style="mso-list:l2 level1 lfo7"><span style="font-size:12.0pt;font-family:Palatino">Community-based programs that support children and families’ access to healthy meals and nutritional education outside the school setting, on weekends
and during the summer<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo7"><span style="font-size:12.0pt;font-family:Palatino">Food and nutritional programs that provide support for expecting mothers and caregivers<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo7"><span style="font-size:12.0pt;font-family:Palatino">Support for programs that address the needs of pre-school children<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo7"><span style="font-size:12.0pt;font-family:Palatino">Health provider/clinician efforts that provide nutritional education to patients and/or food as prescription programming<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo7"><span style="font-size:12.0pt;font-family:Palatino">School-based programs that enhance or augment state and/or federal assistance efforts<o:p></o:p></span></li></ol>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.cybergrants.com/cigna/healthierkidsmentalhealth/index.html__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySud7p-JcjE$">Mental Health</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Our goal is to supplement existing mental health programming, and help close gaps both within and outside the school environment to address loneliness, anxiety, depression, and suicide
prevention. We will fund programs that foster collaboration between stakeholders including school administrators and teachers, clinicians, and local and national nonprofits to address mental health and emotional well-being challenges for children.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Partners are encouraged to leverage one or more of the follow evidence-based programs:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l7 level1 lfo8"><span style="font-size:12.0pt;font-family:Palatino">Trauma Informed Practices (TIPS)<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l7 level1 lfo8"><span style="font-size:12.0pt;font-family:Palatino">Social Emotional Learning (SEL)<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l7 level1 lfo8"><span style="font-size:12.0pt;font-family:Palatino">Positive Behavioral Interventions and Supports (PBIS)<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Both are due September 30, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: September 17.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-21-004.html__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySudTuzoDlU$" target="_blank">Development of Standard Core Clinical Outcomes Assessments (COAs) and Endpoints (UG3/UH3 Clinical
Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for UG3/UH3 cooperative agreements to support the development of a publicly available core set(s)
of COAs and their related endpoints for specific disease indications or for disease impacts that span multiple rare diseases of similar phenotypes.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The UG3/UH3 Phase Innovation Award Cooperative Agreement involves 2 phases. The UG3 phase will provide funding for 1 to 2 years to conduct planning activities. The UH3 phase will provide
funding for 3 to 4 years to projects that successfully complete the planning activities and reach the projected milestones set in the UG3 phase. UH3 phase awards will be awarded after administrative review of eligible UG3 phase awards that have met the scientific
milestone and feasibility requirements necessary for UH3 phase implementation. The number of awards is dependent on the availability of funds. The UG3/UH3 application must be submitted as a single application, and applicants should note specific instructions
for each phase in this FOA. The total award project period will not exceed 5 years.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 14, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: October 1.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-040.html__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySud-YThruU$" target="_blank">Aging, Cancer-Initiating Cells, and Cancer Development (U01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Through this Funding Opportunity Announcement, the National Cancer Institute and National Institute on Aging will promote research to advance the understanding of the mechanistic factors
and cellular interactions during aging that contribute to cancer initiation. Collaborations are strongly encouraged between scientists in the fields of aging biology and cancer biology. Applications should address key questions regarding how hallmarks of aging
that lead to impaired cellular activities (metabolic alterations, proteostasis, epigenetic changes, and DNA repair) and alterations in the microenvironment (inflammation and immunosenescence) contribute to the development and outgrowth of cancer-initiating
cells.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 27, 2020 and February 17, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for October 27, 2020 due date: October 14.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"> <a href="https://urldefense.com/v3/__https://www.alkermes.com/responsibility/pathways__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySudGz0QS9c$" target="_blank">Alkermes Pathways Research Awards Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This program will support projects focused on substance use disorders (SUDs), schizophrenia and bipolar disorder. Open to early career investigators committed to advancing research in
SUDs, schizophrenia or bipolar disorder, the Pathways program provides individual grant amounts of up to $100,000 per project in research focusing on SUD, schizophrenia or bipolar disorder.<o:p></o:p></span></p>
<p class="MsoNormal"><a name="about"></a><a name="Areas"></a><span style="mso-bookmark:about"><b><span style="font-size:12.0pt;font-family:Palatino">Areas of Interest</span></b></span><span style="mso-bookmark:about"><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></span></p>
<span style="mso-bookmark:about"></span>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l4 level1 lfo9"><span style="font-size:12.0pt;font-family:Palatino">Preclinical, clinical, translational and epidemiological research<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo9"><span style="font-size:12.0pt;font-family:Palatino">Research on treatment and patient centered outcomes<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo9"><span style="font-size:12.0pt;font-family:Palatino">Clinical and health economic outcomes using real-world data<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo9"><span style="font-size:12.0pt;font-family:Palatino">Outcomes research supporting continuity of care utilizing telehealth or other technology-based approaches<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Open to Assistant Professors who have not been awarded an R01 or equivalent.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 30, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: October 19.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-024.html__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySud9cRHd3Y$" target="_blank">PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">NIDA is interested in research that addresses research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Current US
Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. Only one clinical trial has evaluated PrEP among PWID and systematic data regarding
the broader use of PrEP among substance users are limited. There is a need to better understand the effects of substance use on PrEP effectiveness and better inform PrEP implementation among substance users. More systematic data are needed regarding the impact
of substance use on PrEP management and adherence, along with investigating potential unintended consequences of PrEP use that may be unique to substance users. This RFA is restricted to projects conducted in the United States, although foreign components
are permitted where they support domestic research in the United States. Applications are encouraged that propose research in states and counties identified in the US Government’s Ending the HIV Epidemic (EtHE) initiative as described here: Ending the HIV
Epidemic: A Plan for America <a href="https://urldefense.com/v3/__https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySudq6GGPzM$">
https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview</a>. Applications to work in locales that are not included in the EtHE initiative must provide an epidemiologic justification for their inclusion in the research.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 12, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: October 29.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-026.html__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySudO2QQ6v4$" target="_blank">Using Human Cell Animal Chimera Brains to Study HIV Latency and Pathology R01 – Clinical Trials
Not Allowed</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement invites applications for pre-clinical and translational research using human cell-mice chimera animals to study HIV pathology in functional live brain
environments, with the presence of abused substances. Research awards are expected to support replicable mechanistic studies that enable the advancement of translational development for the interventions and treatments of HIV-associated neurological disorders
and for the eventual eradication of HIV from brain cells containing HIV provirus.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 13, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: November 2.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-243.html__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySudZnlbdjQ$" target="_blank">Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral,
and Economic Impact of COVID-19 (R01 – Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement aims to support research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) and future public health emergencies, including pandemics. While research related to the direct clinical effects of COVID-19 are supported by other funding opportunities, the purpose of this funding opportunity is to focus on the
role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health
assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">August 20, 2020; December 2, 2020; and March 2, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for August 20, 2020 due date: August 10.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-021.html__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySudH45qCSo$" target="_blank">Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems
of Interest to NIDDK (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement is to support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus
Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. These
include diabetes and other metabolic diseases, obesity, and endocrine, digestive, liver, pancreas, kidney, urological, and hematologic tissues and diseases.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due December 16, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: December 3.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">To search for additional funding opportunities, please visit <a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69">CoM’s
unofficial funding opportunities blog</a>.<o:p></o:p></span></b></p>
</div>
</body>
</html>